Goal: Our newsletter aims at providing regular updates on the science and the truth behind the current pandemic. We are dedicated to bringing the real science to the table and sharing how the truth invalidates the current narrative, for which scientific evidence is now increasingly lacking. We’ll provide an update on a (semi-)weekly basis, on Mondays and/or Fridays. We sincerely hope this newsletter will contribute to raising awareness about the consequences of human intervention in this pandemic, particularly of mass vaccination, from both an individual and public health perspective.
“While no cause-effect conclusions could be inferred from this observation alanalysis, the lack of negative correlations between mask usage and COVID-19 cases and deaths suggest that the widespread use of masks at a time when an effective intervention was most needed, i.e.,during the strong 2020-2021 autumn-winter peak, was not able to reduce COVID-19 transmission. Moreover, the moderate positivec orrelation between mask usage and deaths in Western Europe also suggests that the universal use of masks may have had harmfulunintended consequences.”
“Randomized controlled trials show all-cause mortality reduction from the Covid adenovirus-vector vaccines but not from the mRNA vaccines.”
“A team of researchers from health agencies in Finland, Denmark, Sweden,and Norway found that rates of myocarditis and pericarditis, two forms of potentially life-threatening heart inflammation, were higher in those who had received one or two doses of either mRNA-based vaccine – Pfizer’s or Moderna’s.”
"Vaccine mRNA was detected in 20 serum samples from 15 mothers, out of 74 samples from 21 mothers tested. A total of 10/16 (63%) and 10/25(40%) mothers had detectable vaccine mRNA at day 1-3 of dose 1 and day 7-10 of dose 2 respectively... Five breast milk samples from 4 mothers had detectable vaccine mRNA, out of 309 samples from 31 mothers tested... The median vaccine mRNA amount in both sample types were comparable: 14ng / 100ml (IQR 8-23) in serum compared to 7ng / 100ml (IQR 6-7) in breast milk (p=0.2)."
“This study revealed that wearing face masks might impose a great risk on individuals, which would not be mitigated by a reduction in the infection rate. The use of face masks, therefore, might be unfit, if not contraindicated, as an epidemiologic intervention against COVID-19.”
“While the Delta virus wiped out the variants that preceded it, Omicron has not eliminated Delta, according to a new study from Israel's Ben-Gurion University of the Negev.”
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.